Literature DB >> 725311

Improved pharmacological activity via pro-drug modification: comparative pharmacokinetics of sodium gamma-hydroxybutyrate and gamma-butyrolactone.

J Lettieri, H L Fung.   

Abstract

Although gamma-butyrolactone (GBL) rapidly converts to gamma-hydroxybutyrate (GHB) in vivo, the lactone gave significantly more prolonged hypnotic effects than GHB when equimolar doses were compared both parenterally and orally in rats. Plasma drug concentrations were higher after GBL administration through both routes, consistent with the observed differences in the pharmacological activity of these two compounds. Oral GBL was absorbed much faster than oral GHB, with the dual effects of decreasing potential first-pass metabolism and elevating plasma drug concentrations to the region where capacity-limited elimination is operative. Parenteral GBL produced a slower initial drug plasma clearance than parenteral GHB. In spite of the rapid metabolism of GBL to GHB, the apparent tissue distribution of these two compounds may be different.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 725311

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  17 in total

1.  Modulation of absence seizures by the GABA(A) receptor: a critical rolefor metabotropic glutamate receptor 4 (mGluR4).

Authors:  O C Snead; P K Banerjee; M Burnham; D Hampson
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

2.  An interactive lesson in acid/base and pro-drug chemistry using sodium gamma-hydroxybutyrate and commercial test coasters.

Authors:  Nathaniel A Page; Meaghan Paganelli; Kathleen M K Boje; Ho-Leung Fung
Journal:  Am J Pharm Educ       Date:  2007-06-15       Impact factor: 2.047

3.  Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons.

Authors:  Amy K Goodwin; Roland R Griffiths; P Rand Brown; Wolfgang Froestl; Cornelis Jakobs; K Michael Gibson; Elise M Weerts
Journal:  Psychopharmacology (Berl)       Date:  2006-09-20       Impact factor: 4.530

4.  Alterations in neuronal transport but not blood-brain barrier transport are observed during gamma-hydroxybutyrate (GHB) sedative/hypnotic tolerance.

Authors:  Indranil Bhattacharya; Joseph J Raybon; Kathleen M K Boje
Journal:  Pharm Res       Date:  2006-08-10       Impact factor: 4.200

Review 5.  Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse.

Authors:  Lawrence P Carter; Daniel Pardi; Jane Gorsline; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2009-06-02       Impact factor: 4.492

6.  Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses.

Authors:  S D Ferrara; S Zotti; L Tedeschi; G Frison; F Castagna; L Gallimberti; G L Gessa; P Palatini
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

7.  Cardiovascular responses elicited by intragastric administration of BDL and GHB.

Authors:  Alissa R Hicks; Kurt J Varner
Journal:  J Recept Signal Transduct Res       Date:  2008       Impact factor: 2.092

Review 8.  Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid.

Authors:  Marilyn E Morris; Melanie A Felmlee
Journal:  AAPS J       Date:  2008-06-04       Impact factor: 4.009

9.  Pharmacokinetics of 1,4-butanediol in rats: bioactivation to gamma-hydroxybutyric acid, interaction with ethanol, and oral bioavailability.

Authors:  Ho-Leung Fung; Pei-Suen Tsou; Jurgen B Bulitta; Doanh C Tran; Nathaniel A Page; David Soda; Sun Mi Fung
Journal:  AAPS J       Date:  2008-02-08       Impact factor: 4.009

10.  Effects of monocarboxylate transporter inhibition on the oral toxicokinetics/toxicodynamics of γ-hydroxybutyrate and γ-butyrolactone.

Authors:  Bridget L Morse; Marilyn E Morris
Journal:  J Pharmacol Exp Ther       Date:  2013-02-07       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.